News
NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...
StockStory.org on MSN12d
Biogen (NASDAQ:BIIB) Reports Bullish Q2Biotech company Biogen (NASDAQ:BIIB) in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of ...
Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...
StockStory.org on MSN18d
1 Nasdaq 100 Stock to Target This Week and 2 That UnderwhelmWhile the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures ...
Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated a ‘Neutral’ rating on the stock and raised the price target to $130 from ...
Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...
Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...
StockStory.org on MSN13d
Biogen Earnings: What To Look For From BIIBBiotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know. Biogen ...
Biogen (NASDAQ:BIIB) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financials ...
Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...
Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the September 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the August 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results